Senti Biosciences Reports Exit/Disposal Activities on Jan 3

TL;DR

**Senti Biosciences is reporting costs tied to exiting or disposing of assets, signaling potential restructuring.**

AI Summary

Senti Biosciences, Inc. filed an 8-K on January 5, 2024, reporting an event that occurred on January 3, 2024. This filing indicates that the company is undergoing 'Cost Associated with Exit or Disposal Activities' and 'Other Events,' suggesting potential restructuring or significant operational changes. For investors, this matters because such activities can impact the company's financial health, future prospects, and potentially lead to one-time charges or long-term cost savings, influencing stock valuation.

Why It Matters

This filing signals potential operational restructuring or asset divestment, which could lead to one-time costs or future efficiencies, directly impacting Senti Biosciences' financial performance and stock price.

Risk Assessment

Risk Level: medium — Exit or disposal activities can be costly in the short term but may lead to long-term benefits, creating uncertainty for investors.

Analyst Insight

A smart investor would monitor subsequent filings for details on the nature and financial impact of these 'exit or disposal activities' to assess potential long-term benefits versus short-term costs.

Key Players & Entities

• Senti Biosciences, Inc. (company) — the registrant filing the 8-K
• January 3, 2024 (date) — date of the earliest event reported
• January 5, 2024 (date) — date the 8-K was filed
• 2 Corporate Drive, First Floor South San Francisco , California 94080 (company) — business address of Senti Biosciences, Inc.
• (650) 239-2030 (dollar_amount) — registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share SNTI The Nasdaq Global Market
• $1 m — ance and related costs of approximately $1 million, which are anticipated to be incu

Filing Documents

• snti-20240103.htm (8-K) — 33KB
• a20240105ex991pressrelease.htm (EX-99.1) — 17KB
• senti_logoxpr.jpg (GRAPHIC) — 3KB
• 0001854270-24-000005.txt ( ) — 190KB
• snti-20240103.xsd (EX-101.SCH) — 2KB
• snti-20240103_lab.xml (EX-101.LAB) — 24KB
• snti-20240103_pre.xml (EX-101.PRE) — 13KB
• snti-20240103_htm.xml (XML) — 3KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On January 3, 2024, the Board of Directors (the "Board") of Senti Biosciences, Inc. (the "Company") approved plans to streamline the Company's business operations to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia and to continue support for the clinical development activities of SENTI-301A for the treatment of hepatocellular carcinoma in China through the Company's partnership with Celest Therapeutics. Pursuant to these plans, the Company is reducing its workforce by approximately 37%. The Company expects that these resource allocation efforts, in addition to other expected receivables, will extend its cash runway into the first quarter of 2025. The Company expects to incur one-time estimated severance and related costs of approximately $1 million, which are anticipated to be incurred and recorded in the first quarter of 2024. The estimated charges that the Company expects to incur in connection with these resource allocation efforts are subject to a number of assumptions, and actual results may differ materially from these estimates. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, these resource allocation efforts.

01 Other Events

Item 8.01 Other Events. On January 5, 2024, the Company issued a press release titled, "Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program." A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K, including the documents incorporated herein by reference, contains forward-looking statements, including, but not limited to, statements related to the expected costs associated with termination benefits and the timing, scope and financial impact of the Company's plans including the reduction in force. These forward-looking statements are based on the Company's current expectations and inherently involve significant risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to cost reduction efforts. In addition, the Company's workforce reduction costs may be greater than anticipated and the workforce reduction may have an adverse impact on the Company's development activities and the Company's resource allocation efforts may not generate their intended benefits to the extent or as quickly as anticipated. Risks and uncertainties facing the Company are described more fully in its Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 14, 2023, under the heading "Risk Factors," and other documents that the Company has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Current Report. The Company disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this Current Report, except to the extent required by law.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 5, 2024 titled, "Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SENTI BIOSCIENCES, INC. Date: January 5, 2024 By: /s/ Timothy Lu Name: Timothy Lu, M.D., Ph.D. Title: Chief Executive Officer & President

View Full Filing

View this 8-K filing on SEC EDGAR